SOX2 and cancer: Herreros-Villanueva et al. (2013) further uncovered the role of SOX2 as a CSC maker in PDAC (SOX2+ PDAC) and indicated that aberrant expression of SOX2 could contribute to proliferation, generation of stem-like properties and dedifferentiation of PDAC by controlling EMT phenotypes. Targeting SOX2+ PDAC, therefore, could be a promising therapeutic strategy to root out CSCs in PDAC to prevent cancer progression, drug resistance and recurrence.